Skip to main content

5 Result(s)

within Wijith Munasinghe Remove this filter

and

  1. Article

    Open Access

    Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

    Ilorasertib (ABT-348) inhibits Aurora and VEGF receptor (VEGFR) kinases. Patients with advanced solid tumours participated in a phase 1 dose-escalation trial to profile the safety, tolerability, and pharmacoki...

    Michael L. Maitland, Sarina Piha-Paul, Gerald Falchook… in British Journal of Cancer (2018)

    Download PDF (708 KB) View Article

  2. No Access

    Article

    Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies

    Veliparib is an orally active potent poly(ADP-ribose) polymerase (PARP) inhibitor currently in phase III clinical trials in solid tumors. This phase I study evaluated the pharmacokinetics and mass balance of v...

    Silpa Nuthalapati, Wijith Munasinghe, Vincent Giranda… in Clinical Pharmacokinetics (2018)

  3. Article

    Open Access

    Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study

    Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on corrected QT interval using Fridericia...

    Wijith Munasinghe, Sven Stodtmann, Anthony Tolcher… in Cancer Chemotherapy and Pharmacology (2016)

    Download PDF (496 KB) View Article

  4. No Access

    Article

    Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

    Background Ilorasertib (ABT-348) is a novel inhibitor of Aurora kinase, vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors, and the Src families of tyr...

    Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia… in Investigational New Drugs (2015)

  5. No Access

    Article

    A phase 1 study of ABT-806 in subjects with advanced solid tumors

    Purpose ABT‐806, a humanized recombinant monoclonal antibody, binds a unique epidermal growth factor receptor (EGFR) epitope exposed in the EGFRde2‐7 (EGFRvIII) deletion mutant and other EGFR pro...

    James M. Cleary, David A. Reardon, Nilofer Azad, Leena Gandhi… in Investigational New Drugs (2015)